155 related articles for article (PubMed ID: 8299667)
21. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
Durrington PN; Miller JP
Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
[TBL] [Abstract][Full Text] [Related]
22. The effects of probucol on the levels, structure, composition and metabolism of plasma lipoprotein in rats.
Eisenberg S
Biochim Biophys Acta; 1993 Mar; 1167(1):79-84. PubMed ID: 8461336
[TBL] [Abstract][Full Text] [Related]
23. Probucol protects lipoprotein (a) against oxidative modification.
Naruszewicz M; Selinger E; Dufour R; Davignon J
Metabolism; 1992 Nov; 41(11):1225-8. PubMed ID: 1435295
[TBL] [Abstract][Full Text] [Related]
24. Influence of probucol on cholesterol and lipoprotein metabolism in man.
Kesäniemi YA; Grundy SM
J Lipid Res; 1984 Aug; 25(8):780-90. PubMed ID: 6491523
[TBL] [Abstract][Full Text] [Related]
25. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
[TBL] [Abstract][Full Text] [Related]
26. Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover.
Lock DR; Kuisk I; Gonen B; Patsch W; Schonfeld G
Atherosclerosis; 1983 Jun; 47(3):271-8. PubMed ID: 6882500
[TBL] [Abstract][Full Text] [Related]
27. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
Hunninghake DB; Bell C; Olson L
Atherosclerosis; 1980 Nov; 37(3):469-74. PubMed ID: 7458992
[TBL] [Abstract][Full Text] [Related]
28. Distribution of lipoproteins triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use- The Pacific Northwest Bell Telephone Company health survey.
Wahl PW; Warnick GR; Albers JJ; Hoover JJ; Walden CE; Bergelin RO; Ogilvie JT; Hazzard WR; Knopp RH
Atherosclerosis; 1981 Apr; 39(1):111-24. PubMed ID: 6941788
[TBL] [Abstract][Full Text] [Related]
29. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
Artery; 1993; 20(1):1-18. PubMed ID: 8447724
[TBL] [Abstract][Full Text] [Related]
30. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
Yamashita S; Arai H; Bujo H; Masuda D; Ohama T; Ishibashi T; Yanagi K; Doi Y; Nakagawa S; Yamashiro K; Tanabe K; Kita T; Matsuzaki M; Saito Y; Fukushima M; Matsuzawa Y;
J Atheroscler Thromb; 2021 Feb; 28(2):103-123. PubMed ID: 32336695
[TBL] [Abstract][Full Text] [Related]
31. On the mechanism of plasma cholesterol reduction in the rat given probucol.
Balasubramaniam S; Beins DM; Simons LA
Clin Sci (Lond); 1981 Nov; 61(5):615-9. PubMed ID: 6169481
[TBL] [Abstract][Full Text] [Related]
32. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
Valeri A; Gelfand J; Blum C; Appel GB
Am J Kidney Dis; 1986 Dec; 8(6):388-96. PubMed ID: 3544820
[TBL] [Abstract][Full Text] [Related]
33. Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol.
Komura T; Takahara K; Sugano M; Fujinishi A; Tasaki H; Nakashima Y; Kuroiwa A
Eur J Drug Metab Pharmacokinet; 1997; 22(3):201-6. PubMed ID: 9358199
[TBL] [Abstract][Full Text] [Related]
34. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
Dujovne CA; Harris WS; Gerrond LL; Fan J; Muzio F
Am J Cardiol; 1994 Jul; 74(1):38-42. PubMed ID: 8017303
[TBL] [Abstract][Full Text] [Related]
35. Effects of probucol on low-density lipoprotein catabolism in guinea pigs.
Hidaka K; Takada Y; Matsunaga A; Sasaki J; Arakawa K
Artery; 1992; 19(3):162-76. PubMed ID: 1637257
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Baldassarre D; Franceschini G; Peruzzotti G; Brusoni B; Sirtori CR
J Cardiovasc Pharmacol; 1997 Dec; 30(6):784-9. PubMed ID: 9436818
[TBL] [Abstract][Full Text] [Related]
37. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol.
Mao SJ; Yates MT; Parker RA; Chi EM; Jackson RL
Arterioscler Thromb; 1991; 11(5):1266-75. PubMed ID: 1911712
[TBL] [Abstract][Full Text] [Related]
39. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
40. In vitro studies on the distribution of probucol among human plasma lipoproteins.
Urien S; Riant P; Albengres E; Brioude R; Tillement JP
Mol Pharmacol; 1984 Sep; 26(2):322-7. PubMed ID: 6482877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
